{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T20:16:39Z","timestamp":1772914599380,"version":"3.50.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T00:00:00Z","timestamp":1599523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T00:00:00Z","timestamp":1599523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Racial and Ethnic Health Disparities"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Rationale<\/jats:title>\n                <jats:p>Hypertension, obesity and diabetes are major risk factors associated with morbidities underlying COVID-19 infections. Regression analysis correlated presence of ACE insertion\/deletion (I\/D) polymorphism to COVID-19 incidence and mortality. Furthermore, COVID-19 prevalence correlated to allele frequency of angiotensin-converting enzyme (ACE) deletion (D) polymorphism within the European population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Homozygous ACE deletion polymorphism is associated with increase in ACE and angiotensin II (Ang-II), sustained levels can result in inflammation, fibrosis and organ damage. The ACE DD polymorphism is also associated with hypertension, acute respiratory distress and diabetic nephropathy, all considered high risk for COVID-19 infection and outcomes. The study objective was to describe a biological framework associating ethnic prevalence of ACE deletion polymorphism to COVID-19 comorbidities providing rationale for therapeutic utility of ACE-I\/ARBs to improve outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method and Results<\/jats:title>\n                <jats:p>The Allele Frequency Database (ALFRED) was queried for frequency of rs4646994 representing ACE I\/D polymorphism. In a total of 349 worldwide population samples, frequency of ACE D allele was higher in European, Asian, and Africans cohorts. In the USA, the frequency of ACE D allele was higher in non-Hispanic Black compared with non-Hispanic White and Mexican Americans.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>COVID-19 binding mediated reduction\/inactivation of ACE-II can increase ACE\/Ang-II signalling pathway and related pathologies. The presence of ACE DD polymorphism with COVID-19 infection likely augments ACE\/Ang-II activities, increasing severity of COVID-19 morbidities and impacts outcomes. Thus, ethnic prevalence of ACE DD polymorphism can explain in part the severity of COVID-19 morbidity providing rationale for the use of ACE-I\/ARBs to improve outcomes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40615-020-00853-0","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T08:20:47Z","timestamp":1599726047000},"page":"973-980","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors\/Angiotensin Receptor Blockers"],"prefix":"10.1007","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9403-9421","authenticated-orcid":false,"given":"Rangaprasad","family":"Sarangarajan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Winn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Kiebish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chas","family":"Bountra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elder","family":"Granger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niven R.","family":"Narain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,8]]},"reference":[{"issue":"10230","key":"853_CR1","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/S01406736(20)30690-5","volume":"395","author":"A Saglietto","year":"2020","unstructured":"Saglietto A, D'Ascenzo F, Zoccai GB, De Ferrari GM. COVID-19 in Europe: the Italian lesson. Lancet. 2020;395(10230):1110\u20131. https:\/\/doi.org\/10.1016\/S01406736(20)30690-5.","journal-title":"Lancet"},{"key":"853_CR2","unstructured":"Coronavirus disease 2019 (COVID19) in the EU\/EEA and the UK \u2013 ninth update, 23 April, 2020 Stockholm: ECDC; 2020."},{"issue":"15","key":"853_CR3","doi-asserted-by":"publisher","first-page":"458","DOI":"10.15585\/mmwr.mm6915e3","volume":"69","author":"S Garg","year":"2020","unstructured":"Garg S, Kim L, Whitaker M, O\u2019Halloran A, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 \u2013 COVID-NET, 14 States, March 1\u201330, 2020. Morbidity Mortal Weekly Rep. 2020;69(15):458\u201364.","journal-title":"Morbidity Mortal Weekly Rep"},{"key":"853_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:1\u201310.","journal-title":"Cell"},{"key":"853_CR5","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/path.1570","volume":"203","author":"I Hamming","year":"2004","unstructured":"Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus: a first step in understanding SARS pathogenesis. J Pathol. 2004;203:631\u201363.","journal-title":"J Pathol"},{"issue":"7","key":"853_CR6","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.biocel.2005.01.012","volume":"37","author":"M Kurdi","year":"2005","unstructured":"Kurdi M, De Mello WC, Booz GW. Working outside the system: an update on the unconventional behaviour of the renin-angiotensin systems components. Int J Biochem Cell Biol. 2005;37(7):1357\u201367.","journal-title":"Int J Biochem Cell Biol"},{"key":"853_CR7","doi-asserted-by":"publisher","unstructured":"Kenyon C. ACE-1 I\/D polymorphism associated with COVID-19 incidence and mortality: an ecological study. https:\/\/doi.org\/10.20944\/preprints202004.0262.v1.","DOI":"10.20944\/preprints202004.0262.v1"},{"issue":"3","key":"853_CR8","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.1365-2796.2008.01981.x","volume":"264","author":"F Fyhrquist","year":"2008","unstructured":"Fyhrquist F, Saijonmaa O. Renin\u2013angiotensin system revisited. J Intern Med. 2008;264(3):224\u201336.","journal-title":"J Intern Med"},{"issue":"6","key":"853_CR9","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S0196-9781(97)00011-9","volume":"18","author":"BF Lindberg","year":"1997","unstructured":"Lindberg BF, Gyllstedt E, Andersson KE. Conversion of angiotensin I to angiotensin II by chymase activity in human pulmonary membranes. Peptides. 1997;18(6):847\u201353.","journal-title":"Peptides"},{"issue":"25","key":"853_CR10","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1056\/NEJM199606203342507","volume":"334","author":"TL Goodfriend","year":"1996","unstructured":"Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med. 1996;334(25):1649\u201354.","journal-title":"N Engl J Med"},{"issue":"8","key":"853_CR11","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1042\/CS20060342","volume":"112","author":"S Higuchi","year":"2007","unstructured":"Higuchi S, Ohtsu H, Suzuki H, Shirai H, Frank GD, Eguchi S. Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin Sci (Lond). 2007;112(8):417\u201328.","journal-title":"Clin Sci (Lond)"},{"key":"853_CR12","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1681\/ASN.2006040356","volume":"17","author":"C Ruster","year":"2006","unstructured":"Ruster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol. 2006;17:2985\u201391.","journal-title":"J Am Soc Nephrol"},{"key":"853_CR13","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S1357-2725(02)00271-6","volume":"35","author":"Y Suzuki","year":"2003","unstructured":"Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol. 2003;35:881\u2013900.","journal-title":"Int J Biochem Cell Biol"},{"key":"853_CR14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/emmm.201000080","volume":"2","author":"A Benigni","year":"2010","unstructured":"Benigni A, Paola C, Remuzzi G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med. 2010;2:247\u201357.","journal-title":"EMBO Mol Med"},{"key":"853_CR15","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","volume":"87","author":"M Donoghue","year":"2000","unstructured":"Donoghue M, Hsieh F, Baronas E, Godbout K, et al. A novel angiotensin-converting enzyme related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87:E1\u20139.","journal-title":"Circ Res"},{"key":"853_CR16","doi-asserted-by":"publisher","first-page":"33238","DOI":"10.1074\/jbc.M002615200","volume":"275","author":"SR Tipnis","year":"2000","unstructured":"Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000;275:33238\u201343.","journal-title":"J Biol Chem"},{"key":"853_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.coph.2006.03.001","volume":"6","author":"K Kuba","year":"2006","unstructured":"Kuba K, Imai Y, Penninger JM. Angiotensin-converting enzyme 2 in lung disease. Curr Opin Pharmacol. 2006;6:271\u20136.","journal-title":"Curr Opin Pharmacol"},{"key":"853_CR18","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature03712","volume":"436","author":"Y Imai","year":"2005","unstructured":"Imai Y, Kuba K, Rao S, Yi H, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436:112\u20136.","journal-title":"Nature"},{"issue":"1","key":"853_CR19","first-page":"1","volume":"5","author":"A Abdul-Hafez","year":"2018","unstructured":"Abdul-Hafez A, Mohamed T, Omar H, Shemis M, et al. The renin angiotensin system in liver and lung: impact and therapeutic potential in organ fibrosis. J Lung Pulm Repair Res. 2018;5(1):1\u201312.","journal-title":"J Lung Pulm Repair Res"},{"key":"853_CR20","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.cca.2020.03.031","volume":"505","author":"JR Delanghe","year":"2020","unstructured":"Delanghe JR, Speeckaert MM, De Buyzere ML. The host\u2019s angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections. Clin Chim Acta. 2020;505:192\u20133.","journal-title":"Clin Chim Acta"},{"issue":"2","key":"853_CR21","first-page":"145","volume":"1","author":"PR Gard","year":"2010","unstructured":"Gard PR. Implications of the angiotensin converting enzyme gene insertion\/deletion polymorphism in health and disease: a snapshot review. Int J Mol Epidemiol Genet. 2010;1(2):145\u201357.","journal-title":"Int J Mol Epidemiol Genet"},{"key":"853_CR22","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/00043798-199710000-00013","volume":"4","author":"JA Staessen","year":"1997","unstructured":"Staessen JA, Ginocchio G, Wang JG, Saavedra AP, et al. Genetic variability in the renin-angiotensin system: prevalence of alleles and genotypes. J Cardiovasc Risk. 1997;4:401\u201322.","journal-title":"J Cardiovasc Risk"},{"issue":"2","key":"853_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/ajh.2011.182","volume":"25","author":"RM Ned","year":"2012","unstructured":"Ned RM, Yesupriya A, Imperatore G, Smelser DT, Moonesinghe R, Chang MH, et al. The ACE I\/D polymorphism in US adults: limited evidence of association with hypertension-related traits and sex-specific effects by race\/ethnicity. Am J Hypertens. 2012;25(2):209\u201315.","journal-title":"Am J Hypertens"},{"key":"853_CR24","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1161\/01.RES.0000223145.74217.e7","volume":"98","author":"FA Sayed-Tabatabaei","year":"2006","unstructured":"Sayed-Tabatabaei FA, Isaacs OA, van Duijn CM, Witteman JCM. ACE polymorphisms. Circ Res. 2006;98:1123\u201333.","journal-title":"Circ Res"},{"issue":"4","key":"853_CR25","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1172\/JCI114844","volume":"86","author":"B Rigat","year":"1990","unstructured":"Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion\/deletion polymorphism in the angiotensin I converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86(4):1343\u20136.","journal-title":"J Clin Invest"},{"key":"853_CR26","first-page":"1","volume":"5","author":"J Wang","year":"2015","unstructured":"Wang J, Chen L, Chen B, Meliton A, et al. Chronic activation of the renin-angiotensin system induces lung fibrosis. Sci Rep. 2015;5:1\u201311.","journal-title":"Sci Rep"},{"issue":"1","key":"853_CR27","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1378\/chest.91.1.52","volume":"91","author":"S Idell","year":"1987","unstructured":"Idell S, Kueppers F, Lippman M, Rosen H, et al. Angiotensin converting enzyme in bronchoalveolar lavage in ARDS. Chest. 1987;91(1):52\u20136.","journal-title":"Chest"},{"issue":"1","key":"853_CR28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.5527\/wjn.v4.i1.74","volume":"4","author":"S Mizuiri","year":"2015","unstructured":"Mizuiri S, Ohashi Y. ACE and ACE2 in kidney disease. World J Nephrol. 2015;4(1):74\u201382.","journal-title":"World J Nephrol"},{"issue":"4","key":"853_CR29","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1053\/j.ajkd.2007.11.022","volume":"51","author":"S Mizuiri","year":"2008","unstructured":"Mizuiri S, Hemmi H, Arita M, Ohashi Y, et al. Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am J Kidney Dis. 2008;51(4):613\u201323.","journal-title":"Am J Kidney Dis"},{"key":"853_CR30","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1161\/01.HYP.37.1.46","volume":"37","author":"JV Gainer","year":"2001","unstructured":"Gainer JV, Stein CM, Neal T, Vaughan DE, Brown NJ. Interactive effect of ethnicity and ACE insertion\/deletion polymorphism on vascular reactivity. Hypertension. 2001;37:46\u201351.","journal-title":"Hypertension"},{"issue":"8","key":"853_CR31","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1093\/ajh\/7.8.759","volume":"7","author":"K Duru","year":"1994","unstructured":"Duru K, Farrow S, Wang J-M, Lockette W, Kurtz T. Frequency of a deletion polymorphism in the gene for angiotensin converting enzyme is increased in African Americans with hypertension. Am J Hypertens. 1994;7(8):759\u201362.","journal-title":"Am J Hypertens"},{"key":"853_CR32","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1203\/00006450-199604001-00858","volume":"39","author":"A Asamoah","year":"1996","unstructured":"Asamoah A, Yanamandra K, Thurmon TF, Richter R, Green R, Lakin T, et al. A deletion in the angiotensin converting enzyme (ACE) gene is common among African Americans with essential hypertension. Pediatr Res. 1996;39:142.","journal-title":"Pediatr Res"},{"issue":"4","key":"853_CR33","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1177\/1470320315576255","volume":"16","author":"X Deng","year":"2015","unstructured":"Deng X, Zhang S, Jin K, Li L, Gu W, Liu M, et al. Angiotensin converting enzyme I\/D polymorphism and acute respiratory syndrome. J Renin-Angiotensin-Aldosterone Syst. 2015;16(4):780\u20136.","journal-title":"J Renin-Angiotensin-Aldosterone Syst"},{"key":"853_CR34","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1183\/09031936.00046106","volume":"29","author":"M Adamzik","year":"2007","unstructured":"Adamzik M, Frey U, Sixt S, Knemeyer L, Beiderlinden M, Peters J, et al. ACE I\/D but not AGT (\u22126) A\/G polymorphism is a risk factor for mortality in ARDS. Eur Respir J. 2007;29:482\u20138.","journal-title":"Eur Respir J"},{"key":"853_CR35","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1164\/rccm.2108086","volume":"166","author":"RP Marshall","year":"2002","unstructured":"Marshall RP, Webb S, Bellingan GJ, Montgomery HE, Chaudhari B, McAnulty RJ, et al. Angiotensin converting enzyme insertion\/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. Am J Respir Crit Care Med. 2002;166:646\u201350.","journal-title":"Am J Respir Crit Care Med"},{"key":"853_CR36","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.rmed.2011.06.009","volume":"105","author":"X-M Lu","year":"2011","unstructured":"Lu X-M, Chen G-J, Yang Y, H-B Q. Angiotensin-converting enzyme polymorphism affects outcome of local Chinese with acute lung injury. Respir Med. 2011;105:1485\u201390.","journal-title":"Respir Med"},{"issue":"4","key":"853_CR37","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1097\/01.CCM.0000206107.92476.39","volume":"34","author":"J Jih-Shuin","year":"2006","unstructured":"Jih-Shuin J, Chong-Jen Y, Hao-Chien W, Kuan-Yu C, et al. Polymorphism of the angiotensin-converting enzyme gene affects the outcome of acute respiratory distress syndrome. Crit Care Med. 2006;34(4):1001\u20136.","journal-title":"Crit Care Med"},{"key":"853_CR38","first-page":"861","volume":"79","author":"AE Tsantes","year":"2013","unstructured":"Tsantes AE, Kopterides P, Bonovas S, Bagos PG, Antonakos G, Nikolopoulos GK, et al. Effect of angiotensin converting enzyme gene I\/D polymorphism and its expression on clinical outcome in acute respiratory distress syndrome. Minerva Anestesiol. 2013;79:861\u201370.","journal-title":"Minerva Anestesiol"},{"key":"853_CR39","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s00134-008-1143-3","volume":"34","author":"JJ Burgts","year":"2008","unstructured":"Burgts JJ, Den Uil CA. ACE insertion\/deletion polymorphism in sepsis and acute respiratory distress syndrome. Intensive Care Med. 2008;34:1733.","journal-title":"Intensive Care Med"},{"key":"853_CR40","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1378\/chest.87.2.191","volume":"87","author":"F Fourrier","year":"1985","unstructured":"Fourrier F, Chopin C, Wallaert B, Mazurier C, et al. Compared evolution of plasma fibronectin and angiotensin-converting enzyme levels in septic ARDS. Chest. 1985;87:191\u20135.","journal-title":"Chest"},{"key":"853_CR41","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1038\/ncomms4595","volume":"5","author":"F Huang","year":"2014","unstructured":"Huang F, Guo J, Zou Z, Liu J, Cao B, Zhang S, et al. Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients. Nat Comm. 2014;5:3595\u2013604.","journal-title":"Nat Comm"},{"key":"853_CR42","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.kint.2020.03.005","volume":"97","author":"Y Cheng","year":"2020","unstructured":"Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney impairment is associated with in-hospital death of COVID-19 patients. Kidney Int. 2020;97:829\u201338. https:\/\/doi.org\/10.1016\/j.kint.2020.03.005.","journal-title":"Kidney Int"},{"key":"853_CR43","doi-asserted-by":"publisher","unstructured":"Anti-2019-nCoV Volunteers, Li Z, Wu M, Yao J, et al. Caution on kidney dysfunctions of COVID-19 patients. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.02.08.20021212.","DOI":"10.1101\/2020.02.08.20021212"},{"key":"853_CR44","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s11255-020-02451-9","volume":"52","author":"BM Henry","year":"2020","unstructured":"Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int J Urol Nephrol. 2020;52:1193\u20134. https:\/\/doi.org\/10.1007\/s11255-020-02451-9.","journal-title":"Int J Urol Nephrol"},{"key":"853_CR45","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1053\/j.ajkd.2007.11.022","volume":"51","author":"S Mizuiri","year":"2008","unstructured":"Mizuiri S, Hemmi H, Arita M, Ohashi Y, Tanaka Y, Miyagi M, et al. Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am J Kidney Dis. 2008;51:613\u201323.","journal-title":"Am J Kidney Dis"},{"key":"853_CR46","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1093\/ndt\/gfr600","volume":"27","author":"S Bernardi","year":"2012","unstructured":"Bernardi S, Toffoli B, Zennaro C, Tikellis C, Monticone S, Losurdo P, et al. High-salt diet increases glomerular ACE\/ACE2 ratio leading to oxidative stress and kidney damage. Nephrol Dial Transplant. 2012;27:1793\u2013800.","journal-title":"Nephrol Dial Transplant"},{"key":"853_CR47","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1093\/ndt\/gft320","volume":"28","author":"MJ Soler","year":"2013","unstructured":"Soler MJ, Wysocki J, Batlle D. ACE2 alterations in kidney disease. Nephrol Dial Transplant. 2013;28:2687\u2013269.","journal-title":"Nephrol Dial Transplant"},{"key":"853_CR48","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1210\/en.2006-1287","volume":"148","author":"S Wakahara","year":"2007","unstructured":"Wakahara S, Konoshita T, Mizuno S, Motomura M, Aoyama C, Makino Y, et al. Synergistic expression of angiotensin-converting enzyme (ACE) and ACE2 in human renal tissue and confounding effects of hypertension on the ACE to ACE2 ratio. Endocrinol. 2007;148:2453\u20137.","journal-title":"Endocrinol"},{"key":"853_CR49","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1093\/ndt\/gft038","volume":"28","author":"MA Roberts","year":"2013","unstructured":"Roberts MA, Velkoska E, Ierino FL, Burrell LM. Angiotensin converting enzyme 2 activity in patients with chronic kidney disease. Nephrol Dial Transplant. 2013;28:2287\u201394.","journal-title":"Nephrol Dial Transplant"},{"key":"853_CR50","doi-asserted-by":"crossref","unstructured":"Wang Y, Peng W, Zhang Z, Qiao H, et al. The association of ACE gene polymorphism with diabetic kidney disease and renoprotective efficacy of valsartan. J Renin-Angiotensin-Aldosterone Syst. 2016;17(3):1\u20136.","DOI":"10.1177\/1470320316666749"},{"key":"853_CR51","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.2337\/diacare.24.12.2115","volume":"24","author":"S Fava","year":"2001","unstructured":"Fava S, Ellard S, Azzopardi J, Hattersley AT. ACE gene polymorphism as a prognostic indicator in patients with type 2 diabetes and established renal disease. Diabetes Care. 2001;24:2115\u201320.","journal-title":"Diabetes Care"},{"key":"853_CR52","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1161\/CIRCRESAHA.120.317015","volume":"126","author":"M Gheblawi","year":"2020","unstructured":"Gheblawi M, Wang K, Viveiros A, Nguyen A, et al. Angiotensin converting enzyme 2: SARS-CoV-2 receptor and regulatory of the renin angiotensin system. Circ Res. 2020;126:1456\u201374. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.317015.","journal-title":"Circ Res"},{"issue":"2","key":"853_CR53","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/HJH.0b013e32834f04b6","volume":"30","author":"A Soro-Paavonen","year":"2012","unstructured":"Soro-Paavonen A, Gordin D, Forsblom C, Rosengard-Barlund M, Waden J, Thorn L, et al. Circulating ACE2 activity is increased in patients with type-1 diabetes and vascular complications. J Hypertens. 2012;30(2):375\u201383.","journal-title":"J Hypertens"},{"issue":"8","key":"853_CR54","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1161\/CIRCRESAHA.116.307708","volume":"118","author":"VB Patel","year":"2016","unstructured":"Patel VB, Zhong JC, Grant MB, Oudit GY. Role fo the ACE2\/angiotensin 1-7 axis of the renin-angiotensin system in heart failure. Circ Res. 2016;118(8):1313\u201326.","journal-title":"Circ Res"},{"key":"853_CR55","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1093\/ndt\/gfp065","volume":"24","author":"GY Oudit","year":"2009","unstructured":"Oudit GY, Imai Y, Kuba K, Scholey JW, et al. The role of ACE2 in pulmonary diseases \u2013 relevance for the nephrologist. Nephrol Dial Transplant. 2009;24:1362\u20135.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"853_CR56","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s13054-017-1823-x","volume":"21","author":"A Khan","year":"2017","unstructured":"Khan A, Benthin C, Zeno B, Albertson TE, et al. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care. 2017;21(1):234\u201343.","journal-title":"Crit Care"},{"key":"853_CR57","doi-asserted-by":"publisher","unstructured":"Vinciguerra M, Greco E. Sars-CoV-2 and the black population; ACE2 as shield or blade? Inf Gen Evolution. 2020;84. https:\/\/doi.org\/10.1016\/j.meegid.2020.104361.","DOI":"10.1016\/j.meegid.2020.104361"},{"key":"853_CR58","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","volume":"126","author":"P Zhang","year":"2020","unstructured":"Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126:1671\u201381. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.317134.","journal-title":"Circ Res"},{"key":"853_CR59","doi-asserted-by":"publisher","first-page":"e57278","DOI":"10.7554\/eLife.57278","volume":"9","author":"GP Rossi","year":"2020","unstructured":"Rossi GP, Sanga V, Barton M. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in Covid-19 patients. eLife. 2020;9:e57278. https:\/\/doi.org\/10.7554\/eLife.57278.","journal-title":"eLife"},{"key":"853_CR60","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.mayocp.2020.03.026","volume":"95","author":"F Sanchis-Gomar","year":"2020","unstructured":"Sanchis-Gomar F, Lavie CJ, Perez-Quilis C, Henry BM, Lippi G. Angiotensin-converting enzyme 2 and anti-hypertensives (angiotensin receptor blockers and angiotensin converting enzyme inhibitors) in coronavirus disease 2019 (COVID-19). Mayo Clin Proc. 2020;95:1222\u201330. https:\/\/doi.org\/10.1016\/j.mayocp.2020.03.026.","journal-title":"Mayo Clin Proc"},{"key":"853_CR61","doi-asserted-by":"publisher","unstructured":"Ghosal S, Mukherjee JJ, Sinha B, Gangopadhyay K. The effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on death and severity of disease in patients with coronavirus disease 2019 [COVID-19]: a meta analysis. medRxiv. 2020; his version posted April 28, 2020. https:\/\/doi.org\/10.1101\/2020.04.23.20076661.","DOI":"10.1101\/2020.04.23.20076661"},{"issue":"11","key":"853_CR62","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1177\/1060028018779082","volume":"52","author":"A Helmer","year":"2018","unstructured":"Helmer A, Slater N, Smithgall S. A review of ACE inhibitors and ARBs in black patients with hypertension. Ann Pharmacother. 2018;52(11):1143\u201351.","journal-title":"Ann Pharmacother"}],"container-title":["Journal of Racial and Ethnic Health Disparities"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40615-020-00853-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40615-020-00853-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40615-020-00853-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T23:35:00Z","timestamp":1631057700000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40615-020-00853-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,8]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["853"],"URL":"https:\/\/doi.org\/10.1007\/s40615-020-00853-0","relation":{},"ISSN":["2197-3792","2196-8837"],"issn-type":[{"value":"2197-3792","type":"print"},{"value":"2196-8837","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,8]]},"assertion":[{"value":"2 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}